Antifungal Susceptibility, Enzymatic Activity, PCR-Fingerprinting and ITS Sequencing of Environmental Cryptococcus laurentii Isolates from Uberaba, Minas Gerais, Brazil

Mycopathologia

Volumn 174, Issue 1, 2012, Pages 41-52

  Ferreira Paim, Kennio ^a   Andrade Silva, Leonardo ^a   Mora, Delio Jose ^a   Lages Silva, Eliane ^a   Pedrosa, André Luiz ^a   da Silva, Paulo Roberto ^a   Andrade, Anderson Assunção ^a   Silva Vergara, Mario León ^a  

^a Federal University of Triângulo Mineiro   (Brazil)

Author keywords

(GACA) 4 fingerprinting; Antifungal susceptibility; Cryptococcus laurentii; Internal transcribed spacer; M13 fingerprinting; Phospholipase activity

Indexed keywords

ANTIFUNGAL AGENT; ENZYME; FUNGAL DNA; RIBOSOMAL SPACER DNA;

ANIMAL; ARTICLE; BIRD; BRAZIL; CHEMISTRY; CLUSTER ANALYSIS; CRYPTOCOCCUS; DNA FINGERPRINTING; DNA SEQUENCE; DRUG EFFECT; ENZYMOLOGY; FECES; GENETIC VARIABILITY; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOLECULAR GENETICS; MOLECULAR TYPING; NUCLEOTIDE SEQUENCE; PHYLOGENY; SECRETION;

ANIMALS; ANTIFUNGAL AGENTS; BIRDS; BRAZIL; CLUSTER ANALYSIS; CRYPTOCOCCUS; DNA FINGERPRINTING; DNA, FUNGAL; DNA, RIBOSOMAL SPACER; ENVIRONMENTAL MICROBIOLOGY; ENZYMES; FECES; GENETIC VARIATION; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; MYCOLOGICAL TYPING TECHNIQUES; PHYLOGENY; SEQUENCE ANALYSIS, DNA;

ANIMALIA; AVES; CRYPTOCOCCUS LAURENTII;

EID: 84861999612     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-011-9500-0     Document Type: Article

References (67)

1. Chee HY, Lee KB. Isolation of Cryptococcus neoformans var. grubii (serotype A) from pigeon droppings in Seoul, Korea. J Microbiol (Seoul, Korea). 2005; 43(5): 469-472.
2. Loperena-Alvarez Y, Ren P, Li X, Bopp DJ, Ruiz A, Chaturvedi V, et al. Genotypic characterization of environmental isolates of Cryptococcus gattii from Puerto Rico. Mycopathologia. 2010; 170(4): 279-85.
3. Boekhout T, Theelen B, Diaz M, Fell JW, Hop WC, Abeln EC et al. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology (Reading, England). 2001; 147(Pt 4): 891-907.
4. Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol. 1999; 37(3): 838-40.
5. Sinnott JTt, Rodnite J, Emmanuel PJ, Campos A. Cryptococcus laurentii infection complicating peritoneal dialysis. Pediatr Infect Dis J. 1989; 8(11): 803-5.
6. Lynch JP 3rd, Schaberg DR, Kissner DG, Kauffman CA. Cryptococcus laurentii lung abscess. Am Rev Respir Dis. 1981; 123(1): 135-8.
7. Mocan H, Murphy AV, Beattie TJ, McAllister TA. Fungal peritonitis in children on continuous ambulatory peritoneal dialysis. Scott Med J. 1989; 34(4): 494-6.
8. Krcmery V Jr, Kunova A, Mardiak J. Nosocomial Cryptococcus laurentii fungemia in a bone marrow transplant patient after prophylaxis with ketoconazole successfully treated with oral fluconazole. Infection. 1997; 25(2): 130.
9. Bauters TG, Swinne D, Boekhout T, Noens L, Nelis HJ. Repeated isolation of Cryptococcus laurentii from the oropharynx of an immunocompromized patient. Mycopathologia. 2002; 153(3): 133-5.
10. Furman-Kuklinska K, Naumnik B, Mysliwiec M. Fungaemia due to Cryptococcus laurentii as a complication of immunosuppressive therapy: a case report. Adv Med Sci. 2009; 54(1): 116-9.
11. Tay ST, Na SL, Tajuddin TH. Natural occurrence and growth reaction on canavanine-glycine-bromothymol blue agar of non-neoformans Cryptococcus spp. in Malaysia. Mycoses. 2008; 51(6): 515-9.
12. Rosario I, Soro G, Deniz S, Ferrer O, Acosta F, Padilla D, et al. Presence of C. albidus, C. laurentii and C. uniguttulatus in crop and droppings of pigeon lofts (Columba livia). Mycopathologia. 2009; 169(4): 315-9.
13. Ferreira-Paim K, Andrade-Silva L, Mora DJ, Pedrosa AL, Rodrigues V, Silva-Vergara ML. Genotyping of Cryptococcus neoformans isolated from captive birds in Uberaba, Minas Gerais, Brazil. Mycoses. 2011; 54(5): e294-e300.
14. Averbuch D, Boekhoutt T, Falk R, Engelhard D, Shapiro M, Block C, et al. Fungemia in a cancer patient caused by fluconazole-resistant Cryptococcus laurentii. Med Mycol. 2002; 40(5): 479-84.
15. Cheng MF, Chiou CC, Liu YC, Wang HZ, Hsieh KS. Cryptococcus laurentii fungemia in a premature neonate. J Clin Microbiol. 2001; 39(4): 1608-11.
16. Custis PH, Haller JA, de Juan E Jr. An unusual case of cryptococcal endophthalmitis. Retina (Philadelphia, Pa.). 1995; 15(4): 300-4.
17. Kamalam A, Yesudian P, Thambiah AS. Cutaneous infection by Cryptococcus laurentii. Br J Dermatol. 1977; 97(2): 221-3.
18. Khawcharoenporn T, Apisarnthanarak A, Kiratisin P, Mundy LM, Bailey TC. Evaluation of Cryptococcus laurentii meningitis in a patient with HIV infection: a case report and review of the literature. Hawaii Med J. 2006; 65(9): 260-3.
19. Kunova A, Krcmery V. Fungaemia due to thermophilic cryptococci: 3 cases of Cryptococcus laurentii bloodstream infections in cancer patients receiving antifungals. Scand J Infect Dis. 1999; 31(3): 328.
20. Manfredi R, Fulgaro C, Sabbatani S, Legnani G, Fasulo G. Emergence of amphotericin B-resistant Cryptococcus laurentii meningoencephalitis shortly after treatment for Cryptococcus neoformans meningitis in a patient with AIDS. AIDS Patient Care STDs. 2006; 20(4): 227-32.
21. Ritterband DC, Seedor JA, Shah MK, Waheed S, Schorr I. A unique case of Cryptococcus laurentii keratitis spread by a rigid gas permeable contact lens in a patient with onychomycosis. Cornea. 1998; 17(1): 115-8.
22. Cox GM, McDade HC, Chen SC, Tucker SC, Gottfredsson M, Wright LC, et al. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol. 2001; 39(1): 166-75.
23. Vidotto V, Melhem M, Pukinskas S, Aoki S, Carrara C, Pugliese A. Extracellular enzymatic activity and serotype of Cryptococcus neoformans strains isolated from AIDS patients in Brazil. Rev Iberoam Micol. 2005; 22(1): 29-33.
24. Sanchez A, Escandon P, Castaneda E. In vitro determination of virulence factors activity associated with several Cryptococcus neoformans clinical isolates. Rev Iberoam Micol. 2008; 25(3): 145-9.
25. Ikeda R, Sugita T, Jacobson ES, Shinoda T. Laccase and melanization in clinically important Cryptococcus species other than Cryptococcus neoformans. J Clin Microbiol. 2002; 40(4): 1214-8.
26. Andrade-Silva L, Ferreira-Paim K, Silva-Vergara ML, Pedrosa AL. Molecular characterization and evaluation of virulence factors of Cryptococcus laurentii and Cryptococcus neoformans strains isolated from external hospital areas. Fungal Biol. 2010; 114: 438-45.
27. Luo G, Samaranayake LP, Yau JY. Candida species exhibit differential in vitro hemolytic activities. J Clin Microbiol. 2001; 39(8): 2971-4.
28. Linares CE, de Loreto ES, Silveira CP, Pozzatti P, Scheid LA, Santurio JM, et al. Enzymatic and hemolytic activities of Candida dubliniensis strains. Rev Inst Med Trop Sao Paulo. 2007; 49(4): 203-6.
29. Aller AI, Martin-Mazuelos E, Lozano F, Gomez-Mateos J, Steele-Moore L, Holloway WJ, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother. 2000; 44(6): 1544-8.
30. Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev. 2001; 14(4): 643-658 (table of contents).
31. Costa AK, Sidrim JJ, Cordeiro RA, Brilhante RS, Monteiro AJ, Rocha MF. Urban pigeons (Columba livia) as a potential source of pathogenic yeasts: a focus on antifungal susceptibility of Cryptococcus strains in Northeast Brazil. Mycopathologia. 2010; 169(3): 207-13.
32. Varma A, Kwon-Chung KJ. Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents Chemother. 2010; 54(6): 2303-11.
33. Bernal-Martinez L, Gomez-Lopez A, Castelli MV, Mesa-Arango AC, Zaragoza O, Rodriguez-Tudela JL, et al. Susceptibility profile of clinical isolates of non-Cryptococcus neoformans/non-Cryptococcus gattii Cryptococcus species and literature review. Med Mycol. 2010; 48(1): 90-6.
34. Igreja RP, Lazera Mdos S, Wanke B, Galhardo MC, Kidd SE, Meyer W. Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, Rio de Janeiro. Med Mycol. 2004; 42(3): 229-38.
35. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis. 2003; 9(2): 189-95.
36. 4 primers based on C. neoformans genome project data. J Clin Microbiol. 2007; 45(10): 3427-30.
37. Pedroso RS, Ferreira JC, Lavrador MA, Maffei CM, Candido RC. Evaluation of the experimental inoculation of Cryptococcus albidus and Cryptococcus laurentii in normal mice: virulence factors and molecular profile before and after animal passage. Mycopathologia. 2009; 168(2): 59-72.
38. Sugita T, Takashima M, Ikeda R, Nakase T, Shinoda T. Intraspecies diversity of Cryptococcus laurentii as revealed by sequences of internal transcribed spacer regions and 28S rRNA gene and taxonomic position of C. laurentii clinical isolates. J Clin Microbiol. 2000; 38(4): 1468-71.
39. Ikeda R, Maeda T. Structural studies of the capsular polysaccharide of a non-neoformans Cryptococcus species identified as C. laurentii, which was reclassified as Cryptococcus flavescens, from a patient with AIDS. Carbohydr Res. 2004; 339(3): 503-9.
40. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia. 1982; 20(1): 7-14.
41. Aoki S, Ito-Kuwa S, Nakamura K, Kato J, Ninomiya K, Vidotto V. Extracellular proteolytic activity of Cryptococcus neoformans. Mycopathologia. 1994; 128(3): 143-50.
42. CLSI. Clinical Laboratory Standard Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standards-Third edition. Wayne. PA. CLSI document M27-A3. 2008.
43. Soares MC, Paula CR, Dias AL, Caseiro MM, Costa SO. Environmental strains of Cryptococcus neoformans variety grubii in the city of Santos, SP, Brazil. Rev Inst Med Trop Sao Paulo. 2005; 47(1): 31-6.
44. Leao CA, Ferreira-Paim K, Andrade-Silva L, Mora DJ, da Silva PR, Machado AS et al. Primary cutaneous cryptococcosis caused by Cryptococcus gattii in an immunocompetent host. Med Mycol. 2011; 49(4): 352-5.
45. Souza LK, Fernandes Ode F, Kobayashi CC, Passos XS, Costa CR, Lemos JA, et al. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiania city, Goias, Brazil. Rev Inst Med Trop Sao Paulo. 2005; 47(5): 253-6.
46. Bolano A, Stinchi S, Preziosi R, Bistoni F, Allegrucci M, Baldelli F, et al. Rapid methods to extract DNA and RNA from Cryptococcus neoformans. FEMS Yeast Res. 2001; 1(3): 221-4.
47. Sugita T, Nishikawa A, Ikeda R, Shinoda T. Identification of medically relevant Trichosporon species based on sequences of internal transcribed spacer regions and construction of a database for Trichosporon identification. J Clin Microbiol. 1999; 37(6): 1985-93.
48. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994; 22(22): 4673-80.
49. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987; 4(4): 406-25.
50. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol. 1980; 16(2): 111-20.
51. Kumar S, Tamura K, Nei M. MEGA: molecular evolutionary genetics analysis software for microcomputers. Comput Appl Biosci. 1994; 10(2): 189-91.
52. Johnson LB, Bradley SF, Kauffman CA. Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia. Mycoses. 1998; 41(7-8): 277-80.
53. Kiertiburanakul S, Sungkanuparph S, Pracharktam R. Cryptococcus laurentii Fungemia: a case report. J Infect Dis Antimicrob Agents. 2001; 18(3): 112-4.
54. Shankar EM, Kumarasamy N, Bella D, Renuka S, Kownhar H, Suniti S, et al. Pneumonia and pleural effusion due to Cryptococcus laurentii in a clinically proven case of AIDS. Can Respir J. 2006; 13(5): 275-8.
55. Kordossis T, Avlami A, Velegraki A, Stefanou I, Georgakopoulos G, Papalambrou C, et al. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol. 1998; 36(5): 335-9.
56. Vlchkova-Lashkoska M, Kamberova S, Starova A, Goleva-Mishevska L, Tsatsa-Biljanovska N, Janevska V, et al. Cutaneous Cryptococcus laurentii infection in a human immunodeficiency virus-negative subject. J Eur Acad Dermatol Venereol. 2004; 18(1): 99-100.
57. Simon G, Simon G, Erdos M, Marodi L. Invasive Cryptococcus laurentii disease in a nine-year-old boy with X-linked hyper-immunoglobulin M syndrome. Pediatr Infect Dis J. 2005; 24(10): 935-7.
58. Bloomfield N, Gordon MA, Elmendorf DF, Jr. Detection of Cryptococcus neoformans Antigen in body fluids by latex particle agglutination. In: Proceedings of the society for experimental biology and medicine society for experimental biology and medicine, New York, NY. 1963; 114: 64-67.
59. Bennett JE, Hasenclever HF, Tynes BS. Detection of cryptococcal polysaccharide in serum and spinal fluid: value in diagnosis and prognosis. Trans Assoc Am Phys. 1964; 77: 145-50.
60. Swinne D, De Vroey C. Detection of circulating capsular polysaccharide antigen from Cryptococcus neoformans. J Clin Microbiol. 1992; 30(9): 2521.
61. Maccani JE. Rapid presumptive identification of Cryptococcus neoformans by staphylococcal coagglutination. J Clin Microbiol. 1981; 13(5): 828-32.
62. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Non-neoformans cryptococcal infections: a systematic review. Infection. 2007; 35(2): 51-8.
63. Cafarchia C, Romito D, Coccioli C, Camarda A, Otranto D. Phospholipase activity of yeasts from wild birds and possible implications for human disease. Med Mycol. 2008; 46(5): 429-34.
64. Chan MY, Tay ST. Enzymatic characterisation of clinical isolates of Cryptococcus neoformans, Cryptococcus gattii and other environmental Cryptococcus spp. Mycoses. 2010; 53(1): 26-31.
65. Chen LC, Pirofski LA, Casadevall A. Extracellular proteins of Cryptococcus neoformans and host antibody response. Infect Immun. 1997; 65(7): 2599-605.
66. Pedroso RS, Ferreira JC, Candido RC. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirao Preto, Sao Paulo, Brazil. Memorias do Instituto Oswaldo Cruz. 2006; 101(3): 239-243.
67. Raso TF, Werther K, Miranda ET, Mendes-Giannini MJ. Cryptococcosis outbreak in psittacine birds in Brazil. Med Mycol. 2004; 42(4): 355-62.